View Older Stories View More Recent Stories

Nov 10, 2014 11:01AM Roth Capital Trims PT on Clean Diesel Technologies (CDTI) to $3.50 Following Mixed Q3 Results

Nov 10, 2014 10:21AM Roth Capital Slashes PT on Dendreon (DNDN) to 15c; Sale Unlikely Following Ch. 11 Filing

Nov 7, 2014 09:27AM CTI BioPharma (CTIC) Prices $35M Offering of Convertible Preferred Stock

Nov 7, 2014 06:50AM Roth Capital Positive on TG Therapeutics (TGTX) Following Publication of ASH Abstracts

Nov 6, 2014 03:44PM SolarCity (SCTY) Still 'Buy'-Rated at Roth; Would Likely Withstand Peer Pricing Pressure

Nov 6, 2014 02:09PM Roth Capital Positive on Synta (SNTA) Following Q3 Results; Focus Remains on Ganetespib Phase III GALAXY-2

Nov 6, 2014 11:27AM Roth Capital Remains Positive on Keryx (KERX) Following Q3 Results, Update

Nov 5, 2014 11:40AM Synta's (SNTA) Ganetespib Could See Extra Exclusivity Following FDA Meeting - Roth

Nov 4, 2014 11:56AM Roth Cap Remains Positive on Galena Biopharma (GALE) Following Q3 Results, Update

Nov 4, 2014 08:57AM Roth Capital Starts Ballard Power Systems (BLDP) at Buy

Nov 3, 2014 11:44AM Roth 'Encouraged' by Initial BL-8040 Safety, Pharmacodynamic Data; Maintains BioLineRx (BLRX) at 'Buy'

Nov 3, 2014 07:00AM Roth Capital Starts Hyperion Therapeutics (HPTX) at Buy

Nov 3, 2014 06:57AM Roth Capital Downgrades GP Strategies (GPX) to Neutral

Oct 31, 2014 10:49AM Notable Analyst Rating Changes 10/31: (AXTI) (MPW) (ACHC) Upgraded; (ARR) (AVP) (TASR) Downgraded

Oct 31, 2014 09:24AM UPDATE: Roth Capital Starts Daqo New Energy (DQ) at Buy

Oct 30, 2014 02:35PM Peregrine's (PPHM) Phase Ib IST of Bavituximab Important Progress in Development as NSCLC Treatment - Roth

Oct 29, 2014 02:10PM Roth Affirms GenVec (GNVC) at 'Buy'; Novartis Partnership is Entering 'Prime Time'

Oct 29, 2014 12:24PM Roth Capital Maintains Synta Pharma (SNTA) at 'Buy; Has Initial Meeting with CEO Whitaker

Oct 28, 2014 12:06PM Streetinsider.com's Hot Lunchtime Reads 10/28: (GT) (NE) (COH) (CRIS)

Oct 28, 2014 11:47AM Curis' (CRIS) CUDC-907 IP Protection 'Strong' Following Latest Allowance - Roth Capital

Oct 28, 2014 10:48AM Celator(R) Pharmaceuticals Announces Completion of Its Public Offering and the Exercise in Full of Option to Purchase Additional Units of Common Stock and Warrants to Purchase Common Stock

Oct 27, 2014 01:57PM Roth Capital 'Impressed' with Ligand's (LGND) Q3 Results; Affirms at 'Buy'

Oct 27, 2014 09:38AM Roth Affirms Cytokinetics (CYTK) at 'Buy'; Latest COSMIC-HF Enrollment Data is Encouraging

Oct 27, 2014 07:29AM Stemline's (STML) Valuation is Compelling Heading into 'Data-Rich' 2015 - Roth Capital

Oct 24, 2014 11:15AM Ligand's (LGND) Duavee Will be Significant N-T Revenue Driver; CHMP Opinion is Encouraging - Roth

Oct 24, 2014 10:54AM Roth 'Encouraged' by Verastem's (VSTM) VS-6063 Effect on Biomarkers of CSCs

Oct 24, 2014 08:18AM Roth Capital Downgrades IGI Laboratories (IG) to Neutral

Oct 23, 2014 02:04PM Roth Capital 'Encouraged' by Cytori (CYTX) Receiving FDA Approval to Continue ATHENA

Oct 23, 2014 08:45AM Roth Capital Lifts PT on Ligand (LGND) 32% Ahead of Q3 Results

Oct 22, 2014 08:40AM Roth Affirms Ligand (LGND) at 'Buy' Following Strong Promacta Sales in Q3

Oct 20, 2014 12:53PM Unusual 11 Mid-Day Movers 10/20: (SCOK) (ESI) (SHOR) Higher; (IBIO) (NCR) (CPXX) Lower

Oct 20, 2014 09:59AM Roth Capital Maintains Cytokinetics (CYTK) at 'Buy' Following BENEFIT-ALS Update

Oct 17, 2014 03:31PM Roth Capital Remains Bullish on Hudson Technologies (HDSN); EPA Ruling 'Materially' Better than Expected

Oct 17, 2014 12:59PM Celator Pharmaceuticals (CPXX) Plans Common Stock, Warrants Offering

Oct 17, 2014 12:57PM Celator(R) Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock

Oct 17, 2014 09:24AM Roth Boosts PT on Pharmacyclics (PCYC) to $188; Imbruvica Continues to Gain Traction

Oct 17, 2014 09:01AM Roth Capital Remains Positive on Regeneron (REGN); Latest Outcome Better Positions Eylea as Superior DME Treatment

Oct 16, 2014 02:22PM Roth Capital Positive on Curis (CRIS) Following Q3 Results from Roche/Erivedge

Oct 16, 2014 07:53AM Roth Capital Adds MEI Pharma (MEIP) to Focus List; Multiple Key Inflection Points Coming

Oct 15, 2014 06:54AM Roth Capital Downgrades Durata Therapeutics (DRTX) to Neutral

Oct 14, 2014 07:20AM Roth Capital Starts The Hackett Group (HCKT) at Buy

Oct 13, 2014 11:52AM New Pharmacyclics (PCYC) Collaboration Further Validates Imbruvica; Roth Boosts PT to $185

Oct 13, 2014 09:26AM Roth Sees Visibility in Cytokinetics' (CYTK) CK-107 Program Increasing Significantly Moving Forward

Oct 13, 2014 08:41AM NCE Status Won't Matter for Keryx Biopharma (KERX) - Roth Capital

Oct 10, 2014 04:11PM Cytori Therapeutics (CYTX) Closes on $13.5M in Financing

Oct 10, 2014 10:55AM Notable Analyst Rating Changes 10/10: (IPXL) (EA) (AON) Upgraded; (JCP) (GRPN) (BDSI) Downgraded

Oct 10, 2014 07:10AM Roth Capital Resumes XOMA, Ltd. (XOMA) at Buy

Oct 10, 2014 06:36AM Roth Capital Downgrades BioDelivery Sciences International (BDSI) to Neutral

Oct 9, 2014 05:30PM ARI Network Services, Inc. Announces the Appointment of Chad J. Cooper to Board of Directors

Oct 9, 2014 11:50AM Roth Positive on SolarCity's (SCTY) Loan Program; Sees Tail Risks Ebbing

View More Recent Stories View Older Stories